Browse News
Filter News
Found 99 articles
-
Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants
10/12/2022
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today presented data from the Phase 3 PREVENT-19 trial and Study 307 (Lot Consistency) at the World Vaccine Congress Europe 2022.
-
Moderna Completes Application To U.S. Food And Drug Administration For Emergency Use Authorization Of Omicron-Targeting Bivalent Covid-19 Booster Vaccine, mRNA-1273.222
8/23/2022
Moderna, Inc. announced that it has completed its submission to the U.S. Food and Drug Administration for emergency use authorization for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222.
-
Statement from the Chief Public Health Officer of Canada on July 15, 2022
7/15/2022
The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.
-
There’s quite a bit of movement on the Omicron-specific booster shot and updated supply deals, despite world leaders shifting their attention away from the COVID-19 pandemic.
-
Texas Children's Hospital To Begin Safely Administering COVID-19 Vaccines to Children Aged 6 months to 5 years
6/18/2022
Beginning Tuesday, June 21, Texas Children's Hospital will begin administering both the Pfizer and Moderna COVID-19 vaccines to children aged 6 months to 5 years, following FDA emergency-use authorization and recommendations for safe administration from the CDC.
-
Children under the age of five could be eligible to receive Pfizer-BioNTech's vaccine against COVID-19 as soon as late June.
-
Moderna Reports First Quarter 2022 Financial Results and Provides Business Updates
5/4/2022
Moderna, Inc. today reported financial results and provided business updates for the first quarter of fiscal year 2022.
-
Although it looks that we’re on the downside of the COVID-19 pandemic in the U.S., biopharma companies are still working on developing better treatments and preventions.
-
At this time, 73% of Americans are immune to Omicron, and it could rise to 80% by mid-March. For that and more COVID-19 news, continue reading.
-
The Pfizer-BioNTech vaccine (now Comirnaty®) was fully approved by the U.S. Food and Drug Administration (FDA) on August 23 and boosters of this shot are now available to the most vulnerable Americans.
-
Pfizer and BioNTech reported laboratory assays indicating that three doses of their mRNA COVID-19 vaccine are effective against the new COVID-19 variant, Omicron.
-
The U.S. Centers for Disease Control and Prevention (CDC) reported that the Omicron variant of COVID-19 had been identified in California.
-
Early tests of Regeneron’s antibody cocktail show it isn’t as effective against Omicron while a separate tests of Eli Lilly’s antibody cocktail also demonstrated the same.
-
Omicron has caused the U.S. to install travel bans against several South African countries while vaccine makers rush to test their vaccines against it. For that news and more, continue reading.
-
Between January 4, 2020 and October 30, 2021, COVID-19 accounted for 576 deaths among children 17 and younger, compared to 189 from influenza, according to the CDC.
-
Winter is quickly approaching in the U.S. Vaccine makers aren’t taking a wait-and-see approach but actively preparing for what may come next.
-
COVID-19 Vaccine Clinical Trial in People With Autoimmune Disease Starts at Feinstein Institutes
9/2/2021
As part of a new National Institutes of Health (NIH) coronavirus disease 2019 (COVID-19) vaccine clinical trial, The Feinstein Institutes for Medical Research – the science arm of Northwell Health – delivered its first set of extra shots to eligible New York patients with an autoimmune disease.
-
Statement from the Chief Public Health Officer of Canada on August 27, 2021
8/27/2021
The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.
-
The Infectious Disease Research Institute (IDRI), Duke Human Vaccine Institute, and 3M are working together on a potential vaccine that might protect individuals against multiple variants of SARS-CoV-2.
-
BioSpace takes an in-depth look at the Top 25 of Q1. You should be aware of these biopharma companies as they hold a great future ahead. So, check them out.